ProMIS Neurosciences
Market cap $28.9M 9.0M shares (10-Q, Nov 12, 2026) × $3.21 close Nov 17, 2026
Most recent annual filing: 2026-03-25
- PMN310 FDA feedback2H 2026PMN310 FDA feedback, 2H 2026, notable
- PMN310 corporate update2H 2026PMN310 corporate update, 2H 2026, routine
- PMN310 topline1Q 2027PMN310 topline, 1Q 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (9 active programs)
PMN267
PMN442
PMN311
PMN440
- Undisclosed indication
PMN260
- Undisclosed indication
Technology platforms
EpiSelect · University of British Columbia
Computational discovery platform using thermodynamics and statistical mechanics to model protein misfolding and identify disease-specific conformational epitopes on toxic misfolded proteins. Used to generate selective monoclonal antibodies, intrabodies, and therapeutic vaccines targeting neurodegenerative and misfolded protein diseases including Alzheimer's disease, ALS, Parkinson's disease, MSA, DLB, frontotemporal dementia, and schizophrenia.
Targets: amyloid beta oligomers, alpha-synuclein, TDP-43, tau, SOD1, RACK1, DISC1
EpiSelect
Computational platform to identify conformational epitopes (Disease Specific Epitopes / DSEs) uniquely exposed on toxic misfolded proteins, used to generate misfolding-specific antibodies and vaccine candidates; disease focus: Alzheimer's disease, ALS, frontotemporal dementia, multiple system atrophy, Parkinson's disease
Targets: amyloid-beta oligomers, TDP-43, alpha-synuclein, Aβ oligomers
TXP1 · Ossianix
Next-generation brain-selective shuttling technology based on a deimmunized, single-domain VNAR antibody scaffold targeting transferrin receptor 1 (TfR1); enables enhanced CNS delivery of therapeutic antibodies; focus area: Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative diseases
Targets: TfR1
Capital (as filed)
- Cash
- $44.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $34K Sep 30, 2026
- Operating cash flow
- −$9.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $44.1M cash, runway through 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
- 2026-11-13 UPDATE: ProMIS Neurosciences (PMN) - The Rebuttal Deck 🔒 Paid
- 2026-10-31 UPDATE: ProMIS Neurosciences (PMN) - Someone Else’s Exam, ProMIS’s Grade ★ Distilled Pro
- 2026-07-28 UPDATE: ProMIS Neurosciences (PMN) - The Interim Gets a Date 🔒 Paid
- 2026-07-28 UPDATE: ProMIS Neurosciences (PMN) - The Low-Information Print That Wasn’t 🔒 Paid
- 2026-07-07 ProMIS Neurosciences (PMN) — Scientific Deep Dive for PMN310 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on ProMIS Neurosciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-07-07 Watch ProMIS Neurosciences (PMN) — Scientific Deep Dive for PMN310 and Pipeline Products The oligomer thesis is coherent and the syndicate is elite, but PMN310 has zero human efficacy data and Acumen's sabirnetug reads out first, making the cost of waiting opportunity rather than principal.
- 2026-07-28 Watch UPDATE: ProMIS Neurosciences (PMN) - The Interim Gets a Date The blinded interim is a safety confirmation the market has already granted rather than the efficacy read the story needs, and the two gating events that actually change risk/reward arrive later.
- 2026-07-28 Speculative buy speculative UPDATE: ProMIS Neurosciences (PMN) - The Low-Information Print That Wasn't Safety differentiation is now an observed human result in the highest-ARIA-risk genotypes and two independent tau-pathway markers moved favorably against rising natural history, warranting a starter speculative position.
- 2026-10-31 Watch UPDATE: ProMIS Neurosciences (PMN) - Someone Else's Exam, ProMIS's Grade Sabirnetug failed cleanly in the first large test of oligomer selectivity against a clinical endpoint, destroying the class thesis that underpinned the upgrade, despite PMN310's own data being unchanged.
- 2026-11-13 Watch UPDATE: ProMIS Neurosciences (PMN) - The Rebuttal Deck ProMIS's case that PMN310 differs from sabirnetug is coherent but untested, the FDA meeting has slipped past the data, and the thesis gets tested at Q1 2027 topline with nothing in the new filings changing the read.
- Long call · opened Jul 29, 2026 at $14.06 · closed Nov 2, 2026 (downgraded to WATCH from long) at $3.00 · -78.7% vs XBI +2.8%
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Completion of all patient visits is expected in the fourth quarter of 2026, with unblinded 12-month topline data, including the full safety data set, a detailed panel of biomarkers, and cognitive outcomes, anticipated in the first quarter of 2027 following database lock and statistical analysis.”
matched to PMN310 · topline data
-
-
-
“We look forward to the 12-month unblinded topline results from PRECISE-AD, expected in the first quarter of 2027, which will include cognitive outcomes, and we believe will represent an important next step in evaluating PMN310’s potential for patients with early AD.”
matched to PMN310 · topline data / matched to PMN310 · regulatory submission
-
-
-
“Completion of all patient visits is expected in the fourth quarter of 2026, with unblinded 12-month topline data, including the full safety data set, a detailed panel of biomarkers, and cognitive outcomes, anticipated in the first quarter of 2027 following database lock and statistical analysis. Expenditures for PMN310 in the three and six months ended June 30, 2026, were approximately $7.8 million and $14.0 million, respectively, not including allocations of senior management time.”
matched to PMN310 · topline data / matched to PMN310 · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (26)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
- Nov 12, 2026ReleaseProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateProMIS's Q3 numbers show burn decelerating to ~$8.2M/quarter as PRECISE-AD wraps patient visits, $44.1M cash still on hand, and a fresh 7.73% Schedule 13G from Adage Capital Management — a new institutional name that wasn't in the January PIPE syndicate — arriving the same day management leans into the ALTITUDE-AD failure as competitive differentiation ahead of Q1 2027 topline.
- Nov 12, 20268-KCurrent report: Reg FD disclosure · EX-99.1→ BD updateSummary on the 8-K
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 5, 2026ReleaseProMIS Neurosciences to Participate in Upcoming Conferences in November
- Nov 3, 2026ReleaseProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
- Oct 6, 2026ReleaseProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
- Sep 30, 2026ReleaseUpcoming Conferences and Events in October
- Sep 1, 2026ReleaseProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
- Aug 13, 2026ReleaseProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → PMN pipeline
- Aug 13, 202610-QQuarterly report
- Aug 3, 2026ReleaseProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
- Jul 28, 2026ReleaseProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
- Jul 28, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → PMN pipeline
- Jul 27, 2026ReleaseProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
- May 20, 20268-KCurrent report: officer / director change, shareholder vote
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 9, 2026DEFA14AProxy soliciting material
- Apr 9, 2026DEF 14AProxy statement
- Mar 25, 2026S-3Shelf registration
- Mar 25, 20268-KCurrent report: results of operations · EX-99.1
- Mar 25, 202610-KAnnual report
- Mar 18, 2026S-3Shelf registration
18 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 12, 2026SCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- May 29, 2026S-8Employee plan registration
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 7, 2026SCHEDULE 13G/A13G amendment
- Apr 9, 2026ARSAnnual report to shareholders
- Apr 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 2, 2026EFFECTRegistration effective
- Mar 31, 2026UPLOADUPLOAD
- Mar 31, 2026CORRESPCORRESP
- Mar 26, 2026EFFECTRegistration effective
- Mar 24, 2026CORRESPCORRESP
- Mar 23, 2026UPLOADUPLOAD
- Mar 18, 2026SCHEDULE 13GPassive >5% holder (13G)